bioAffinity Technologies
BIAF
15 hedge funds and large institutions have $132K invested in bioAffinity Technologies in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
0.15% less ownership
Funds ownership: 3.44% → 3.29% (-0.15%)
73% less capital invested
Capital invested by funds: $497K → $132K (-$365K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$13.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.8K |
| 3 |
HF
HRT Financial
New York
|
+$11.5K |
| 4 |
VHAM
Van Hulzen Asset Management
El Dorado Hills,
California
|
+$9.9K |
| 5 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
+$4.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$51.4K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$13.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12.4K |
| 4 |
OC
Oarsman Capital
Milwaukee,
Wisconsin
|
-$2.23K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.93K |
BIAF Hedge Fund Activity: Q1 2025 in Review
15 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q1 2025, worth a combined $132K — down 73% from $497K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BIAF positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Warberg Asset Management, opening a new position worth an estimated $13.7K. The largest seller was Vanguard Group, cutting an estimated $51.4K.
- 15 institutional investors held bioAffinity Technologies (BIAF) as of Q1 2025, up from 14 in Q4 2024.
- Funds reported $132K of bioAffinity Technologies stock for Q1 2025, down 73% quarter-over-quarter.
- 4 funds opened new bioAffinity Technologies positions in Q1 2025 and 3 closed out, a net change of +1 holder.
- The largest bioAffinity Technologies buyer in Q1 2025 was Warberg Asset Management, an estimated $13.7K added.
- The largest bioAffinity Technologies seller in Q1 2025 was Vanguard Group, an estimated $51.4K sold.
Based on aggregated 13F filings for Q1 2025.